John Alford, MD
Orthopaedic Surgery · Warwick, RINPI 1588663587
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (41.7%), education and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Arthrex at 42.8% of the total. Reporting peaked in 2020 at $1,669 and has fallen 93.7% since, to $104 in 2025. That places this record below the midpoint for orthopaedic surgery clinicians in RI, where the typical reported total is $2,875.
Across 17 payments — averaging $133.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$973
- Kairos Surgical Inc$695
- Stryker$423
- Bioventus LLC$74
- Ferring Pharmaceuticals Inc.$57
- Teva Pharmaceuticals USA, Inc.$34
- plus $19 from 1 others
What the payments were for
- Travel & lodging$94942%
- Food & beverage$62327%
- Education$70431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 3 | $973 |
| Kairos Surgical Inc | 1 | $695 |
| Stryker | 5 | $423 |
| Bioventus LLC | 2 | $74 |
| Ferring Pharmaceuticals Inc. | 3 | $57 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Pacira Pharmaceuticals Incorporated | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,276 in reported general payments places this provider in the 45th percentile of 124 orthopaedic surgery providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylprednisolone | 315 | $2,443 |
| Naproxen | 11 | $144 |
| Celecoxib | 12 | $102 |
| Meloxicam | 18 | $64 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in Warwick
- Philip ReillyWarwick$12K
- Christopher ChihlasWarwick$11K
- Nicholas BradyWarwick$9K
- Jonathan GastelWarwick$4K
- Brandon LentineWarwick$4K
- Anthony BuonannoJohnston$2M
- Alan DanielsEast Providence$1.9M
- Robert MarchandWakefield$1.4M
- Michael BradleyWakefield$1.4M
- Edward PaxtonProvidence$244K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.